Parkinson disease (PD) is the second most common neurodegenerative disorder, with a prevalence and incidence rate that increases significantly with age. In North America, an estimated 1% of the population older than 65 years has PD. During the past decade, our understanding of this disease has been radically transformed, particularly regarding its neuropathology, molecular biology, and genetics. Nonetheless, PD remains clinically defined, using the comprehensive neurological examination as the gold standard and clinical measures such as the Unified Parkinson Disease Rating Scale (UPDRS) and the Hoehn & Yahr (H&Y) disability staging to confirm diagnosis and to assess disease progression.1,2
Schiess M, Oh I. Serum Uric Acid and Clinical Progression in Parkinson Disease: Potential Biomarker for Nigrostriatal Failure. Arch Neurol. 2008;65(6):698–699. doi:10.1001/archneur.65.6.698
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: